RESUMEN
BACKGROUND/AIMS: Hepatocellular carcinoma is one of the most commonly diagnosed malignant tumors in the world, and it typically has a poor prognosis. Extensive studies have examined the effects of non-steroidal anti-inflammatory drugs selective to COX-2 on the chemoprevention of various tumors. The objective of this study is to observe the effect of celecoxib on the development of liver tumors in rats. MATERIAL AND METHODS: Hepatocellular carcinoma was induced in a group of 75 rats with the carcinogen diethylnitrosamine. The animals were divided into 5 groups. Three groups received various doses of celecoxib, one group received indomethacin, and a control group received no non-steroidal selective anti inflammatory drugs. RESULTS: The experimental model was considered to be successful because 78% of the rats in the control group developed liver tumors. The number of neoplastic lesions was similar among the celecoxib, indomethacin and control groups, although the nodule diameter of the lesions was smaller in the celecoxib group. Better results were observed in animals that received celecoxib at doses of 6 and 9 mg/kg/ day; 4 rats in these groups did not show any neoplastic histological lesions, and a greater proportion of the nodules in the other animals in these groups were benign than in the groups that did not use celecoxib. CONCLUSIONS: These results suggest that celecoxib may play a role in modifying the natural history of hepatocellular carcinoma development.
Asunto(s)
Anticarcinógenos/farmacología , Carcinoma Hepatocelular/prevención & control , Transformación Celular Neoplásica/efectos de los fármacos , Inhibidores de la Ciclooxigenasa 2/farmacología , Dietilnitrosamina , Neoplasias Hepáticas Experimentales/prevención & control , Hígado/efectos de los fármacos , Pirazoles/farmacología , Sulfonamidas/farmacología , Animales , Carcinoma Hepatocelular/inducido químicamente , Carcinoma Hepatocelular/enzimología , Carcinoma Hepatocelular/patología , Celecoxib , Transformación Celular Neoplásica/inducido químicamente , Transformación Celular Neoplásica/metabolismo , Transformación Celular Neoplásica/patología , Ciclooxigenasa 2/metabolismo , Indometacina/farmacología , Hígado/enzimología , Hígado/patología , Neoplasias Hepáticas Experimentales/inducido químicamente , Neoplasias Hepáticas Experimentales/enzimología , Neoplasias Hepáticas Experimentales/patología , Masculino , Ratas , Factores de TiempoRESUMEN
Os autores propuseram-se avaliar a relação entre a erradicação do helicobacter pylori (HP) em pacientes com úlcera duodenal (UD) e o desenvolvimento de esofagite de refluxo. Para tanto, avaliaram prospectivamente, com duas endoscopias realizadas com intervalo de seis meses cada, 29 pacientes comUD e Hp positivo, tratados com esquema tríplice de antibióticos. No final do seguimento de 12 meses observou-se incidência de esofagite péptica em 25por cento dos casos. Concluiu-se, a despeito do pequeno número de casos e do curto seguimento, que a incidência de esofagite endoscópica é elevada em pacientes com UD após tratamento eo HP.
